Biological therapy became available for psoriasis with the introduction of alefacept at the
beginning of this century. Up to then, systemic treatment options comprised small molecule …

Background An urgent need exists in the United States to establish treatment goals in
psoriasis. Objective We aim to establish defined treatment targets toward which clinicians …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the
United States population. This guideline addresses important clinical questions that arise in …

Psoriasis is a common disease, which has a considerable impact on the healthcare system.
Therefore, appropriate use of therapeutic resources is very important. Management of …

Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …

Psoriasis is a common disease, which has a considerable impact on patients and the health
care system. Treatment approaches to the disease may be various because some issues …

La psoriasis es un proceso inflamatorio crónico y sistémico con múltiples comorbilidades.
Entre las más frecuentes se encuentran las enfermedades mentales y en especial la …

Background and objectives A new, updated AEDV Psoriasis Group (GPs) consensus
document on the treatment of moderate to severe psoriasis was needed owing to the …

Psoriasis is a chronic inflammatory disease with an established genetic background. The
HLA-Cw* 06 allele and different polymorphisms in genes involved in inflammatory …